KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Total Current Liabilities (2016 - 2026)

Pacira BioSciences has reported Total Current Liabilities over the past 17 years, most recently at $108.8 million for Q1 2026.

  • For Q1 2026, Total Current Liabilities fell 65.44% year-over-year to $108.8 million; the TTM value through Mar 2026 reached $108.8 million, down 65.44%, while the annual FY2025 figure was $120.6 million, 61.09% down from the prior year.
  • Total Current Liabilities for Q1 2026 was $108.8 million at Pacira BioSciences, down from $120.6 million in the prior quarter.
  • Over five years, Total Current Liabilities peaked at $314.7 million in Q1 2025 and troughed at $92.7 million in Q2 2024.
  • A 5-year average of $169.6 million and a median of $120.6 million in 2025 define the central range for Total Current Liabilities.
  • Biggest five-year swings in Total Current Liabilities: tumbled 71.64% in 2022 and later surged 237.86% in 2025.
  • Year by year, Total Current Liabilities stood at $147.8 million in 2022, then crashed by 34.1% to $97.4 million in 2023, then skyrocketed by 218.25% to $309.9 million in 2024, then crashed by 61.09% to $120.6 million in 2025, then dropped by 9.79% to $108.8 million in 2026.
  • Business Quant data shows Total Current Liabilities for PCRX at $108.8 million in Q1 2026, $120.6 million in Q4 2025, and $107.1 million in Q3 2025.